EUGENIE S KLEINERMAN to Phosphatidylethanolamines
This is a "connection" page, showing publications EUGENIE S KLEINERMAN has written about Phosphatidylethanolamines.
Connection Strength
2.767
-
Liposomal muramyl tripeptide (CGP 19835A lipid) therapy for resectable melanoma in patients who were at high risk for relapse: an update. Cancer Biother Radiopharm. 1998 Oct; 13(5):363-8.
Score: 0.160
-
Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide. Hematol Oncol Clin North Am. 1995 Aug; 9(4):927-38.
Score: 0.128
-
Liposomal MTP-PE: a promising new biologic response modifier. Oncol Nurs Forum. 1995 Jun; 22(5):809-16.
Score: 0.127
-
Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation. J Immunother Emphasis Tumor Immunol. 1995 Apr; 17(3):181-93.
Score: 0.125
-
Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol. 1995 Apr; 18(2):93-9.
Score: 0.125
-
Administration of liposomal MTP-PE by the local physician: the role of the research nurse. Cancer Pract. 1995 Jan-Feb; 3(1):42-6.
Score: 0.123
-
Liposomal muramyl tripeptide upregulates adhesion molecules on the surface of human monocytes. Oncol Res. 1995; 7(5):253-7.
Score: 0.123
-
Liposomal MTP-PE. J Pediatr Oncol Nurs. 1994 Oct; 11(4):161-3.
Score: 0.121
-
Liposomal muramyl tripeptide up-regulates interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 gene expression in human monocytes. J Pharmacol Exp Ther. 1994 Feb; 268(2):1032-9.
Score: 0.116
-
Liposome-encapsulated muramyl tripeptide up-regulates monocyte chemotactic and activating factor gene expression in human monocytes at the transcriptional and post-transcriptional levels. Cancer Immunol Immunother. 1994 Jan; 38(1):16-22.
Score: 0.115
-
Effect of Adriamycin on liposomal muramyl tripeptide's ability to up-regulate monocyte cytokine expression. Cancer Immunol Immunother. 1993 Nov; 37(6):408-11.
Score: 0.114
-
Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy. J Immunother Emphasis Tumor Immunol. 1993 Nov; 14(4):286-92.
Score: 0.114
-
Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments. Pediatr Blood Cancer. 2014 Feb; 61(2):238-44.
Score: 0.112
-
Anti-(tumor necrosis factor) alters the response of human monocytes to liposomal muramyl tripeptide. Cancer Immunol Immunother. 1993 Aug; 37(3):203-8.
Score: 0.112
-
Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma. Cancer Treat Res. 1993; 62:101-7.
Score: 0.107
-
Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): can ibuprofen reduce fever and chills without compromising immune stimulation? Cancer Immunol Immunother. 1993; 36(1):45-51.
Score: 0.107
-
Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. J Clin Oncol. 1992 Aug; 10(8):1310-6.
Score: 0.104
-
Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid). Cancer Immunol Immunother. 1992; 34(4):211-20.
Score: 0.100
-
Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma. J Clin Oncol. 1991 Feb; 9(2):259-67.
Score: 0.094
-
Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro. Cancer Commun. 1991; 3(10-11):313-21.
Score: 0.093
-
Liposomal MTP-PE for the adjuvant therapy of osteosarcoma. Prog Clin Biol Res. 1990; 343:263-79.
Score: 0.087
-
Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Cancer. 2009 Nov 15; 115(22):5339-48.
Score: 0.086
-
Activation of tumoricidal properties in monocytes from cancer patients following intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine. Cancer Res. 1989 Aug 15; 49(16):4665-70.
Score: 0.085
-
Biologic response modifiers in pediatric cancer. Hematol Oncol Clin North Am. 2001 Aug; 15(4):723-40, ix.
Score: 0.049
-
Impairment of lymphocyte locomotion in the tumor microenvironment and the effect of systemic immunotherapy with liposome-encapsulated muramyl-tripeptide-phosphatidylethanolamine. Cancer Immunol Immunother. 1995 Jan; 40(1):57-64.
Score: 0.031
-
Cytokine production and immune cell activation in melanoma patients treated with liposomal muramyl tripeptide (CGP 19835A lipid). Cancer Biother. 1993; 8(4):307-18.
Score: 0.027
-
Sequential therapy with chemotherapeutic drugs and liposome-encapsulated muramyl tripeptide: determination of potential interactions between these agents. Oncol Res. 1992; 4(10):413-8.
Score: 0.025
-
Differential release of TNF-alpha, IL 1, and PGE2 by human blood monocytes subsequent to interaction with different bacterial derived agents. Lymphokine Res. 1990; 9(4):449-63.
Score: 0.022
-
Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients. J Clin Oncol. 1989 Dec; 7(12):1915-25.
Score: 0.022
-
Human monocytes activated by immunomodulators in liposomes lyse herpesvirus-infected but not normal cells. Science. 1984 Jun 01; 224(4652):1007-9.
Score: 0.015